Special Issue

The Impact of Treatment Resistance in Prostate Cancer

Message from the Guest Editor

The past decade of genomic profiling has proven that prostate cancer (PCa) is a heterogeneous disease, and the cellular and extracellular factors responsible for prostate cancer progression and therapeutic resistance remain unclear. Most patients initially respond well to androgen deprivation therapy (ADT). However, almost all patients will progress to castration-resistant prostate cancer (CRCP), which has no effective treatments. The therapeutic landscape for prostate cancer has dramatically changed due to advances in ADT, radiation, and the introduction of immunotherapy. While these treatments have shown success and improved patient outcomes, they are not curative and select for more aggressive, highly resistant forms of prostate cancer. Therefore, there is a need for a complete understanding of the cellular and tumor microenvironmental factors that facilitate therapeutic resistance, not just the androgen receptor (AR)'s signaling cascade, to identify new drug targets. The objective of this collection is to highlight the latest insights into PCa progression, the mechanisms of drug resistance, and new approaches to targeted therapy.

Guest Editor

Dr. Noel Andrew Warfel

Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ, USA

Deadline for manuscript submissions

closed (10 December 2025)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/230583

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)